In GNB3 TT subjects , FDC I/H improved the CS ( FDC I/H = 0.50 1.6 ; placebo = -0.11 1.8 , p = 0.02 ) , QoL ( FDC I/H = 0.69 1.4 ; placebo = 0.24 1.5 , p = 0.04 ) , and event-free survival ( hazard ratio : 0.51 , p = 0.047 ) , but not in subjects with the C allele ( for CS , FDC I/H = -0.05 1.7 ; placebo = -0.09 1.7 , p = 0.87 ; for QoL , FDC I/H = 0.28 1.5 ; placebo = 0.14 1.5 , p = 0.56 ; and for event-free survival , p = 0.35 ) .